U.S. FDA approves bluebird bio's gene therapy for a rare neurological
disorder
Send a link to a friend
[September 19, 2022]
The U.S. Food and Drug
Administration (FDA) has approved Bluebird bio's gene therapy for the
treatment of a rare neurological disorder, the company said late on
Friday.
"SKYSONA is the first FDA approved therapy shown to slow the progression
of neurologic dysfunction in boys" with early, active Cerebral
Adrenoleukodystrophy (CALD), the company said in a statement, saying
CALD is a "devastating and fatal neurodegenerative disease."
Bluebird said it anticipates commercial product will be available by the
end of 2022 through a limited number of qualified treatment centers in
the United States.
In August, the company's beti-cel therapy secured FDA approval to treat
a rare blood disorder that was priced at a record $2.8 million, the most
expensive treatment to date.
CALD is caused by mutations in a gene called ABCD1 that leads to the
buildup of very long-chain fatty acids in the brain and spinal cord. It
typically occurs in boys between the ages of 3 and 12.
[to top of second column]
|
![](../images/091922PIX/health9.jpg)
Signage is seen outside of the Food and
Drug Administration (FDA) headquarters in White Oak, Maryland, U.S.,
August 29, 2020. REUTERS/Andrew Kelly/File Photo
![](http://archives.lincolndailynews.com/2019/Sep/05/images/ads/current/stclara_lda_SPONSOR_090519.png) Eli-cel adds functional copies of
the ABCD1 gene in a patient's stem cells to help produce a protein
required to break down the long-chain fatty acids.
The approval was largely expected after the drug received unanimous
endorsement from a panel of outside advisers to the FDA in June.
(Reporting by Mrinalika Roy and Jaiveer Shekhawat in Bengaluru;
Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |